Universal reference book for medicines
Product name: RAKSTAN-SANOVEL (RAXTAN-SANOVEL)

Active substance: flurbiprofen

Type: NSAIDs

Manufacturer: SANOVEL PHARMACEUTICAL PRODUCTS Ind.
(Turkey)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
NSAIDs.
Has a pronounced analgesic, anti-inflammatory and antipyretic activity. The mechanism of action is associated with inhibition of COX and inhibition of prostaglandin synthesis. It inhibits the aggregation of platelets.
PHARMACOKINETICS
After ingestion, it is well and completely absorbed from the digestive tract.
C max is reached after 1.5 hours. The connection with plasma proteins is more than 90%.Metabolised in the liver. T 1/2 about 6 hours. It is excreted by the kidneys: 20% - unchanged, the rest - in the form of metabolites.
INDICATIONS
Rheumatoid arthritis, deforming osteoarthritis, ankylosing spondylitis, acute bursitis and tenosynovitis, soft tissue damage;
pain syndrome (weak and moderate intensity): arthralgia, myalgia, neuralgia, migraine, dental and headache, algodismenorea, pain with injuries, burns; febrile syndrome with colds and infectious diseases.
With topical application in ophthalmology: inflammation of the anterior part of the eye after surgery and laser treatment, prevention of miosis during surgery, prevention of postoperative reactive inflammation of the eyes.

DOSING MODE
Inside or rectally 50-100 mg 2-3 times / day.

SIDE EFFECT
On the part of the digestive system: dyspepsia (nausea, vomiting, heartburn, diarrhea), NSAID-gastropathy, abdominal pain, impaired liver function;
with prolonged use in large doses - ulceration of the mucous membrane of the gastrointestinal tract, bleeding (gastrointestinal, hemorrhoidal, of the gums).
From the cardiovascular system: increased blood pressure, tachycardia, heart failure.

From the hemopoietic system: rarely - anemia (iron deficiency, hemolytic, aplastic), agranulocytosis, leukopenia, thrombocytopenia.

From the central nervous system and peripheral nervous system: headache, dizziness, drowsiness or insomnia, asthenia, depression, amnesia, tremor, agitation, rarely - ataxia, paresthesia, impaired consciousness.

From the side of the urinary system: tubulointerstitial nephritis, edematous syndrome, impaired renal function.

Allergic reactions: skin rash, itching, urticaria, bronchospasm, photosensitivity, Quincke's edema, anaphylactic shock.

Other: hearing loss, tinnitus, increased sweating.

With topical application in ophthalmology: burning, irritation of the conjunctiva.

CONTRAINDICATIONS
Erosive-ulcerative lesions of the gastrointestinal tract in the acute phase, aspirin triad (bronchial asthma, vasomotor rhinitis, intolerance to acetylsalicylic acid), pregnancy, lactation, hypersensitivity to NSAIDs, heart failure, edema, arterial hypertension, hemophilia, hypocoagulation, hepatic insufficiency, CRF, hearing loss, pathology of the vestibular apparatus, deficiency of glucose-6-phosphate dehydrogenase, oppression of bone marrow hematopoiesis, early childhood.

It is not applied rectally to inflammatory diseases of the rectum and perianal region.

With topical application in ophthalmology: hypersensitivity, herpetic keratitis.

PREGNANCY AND LACTATION
Flurbiprofen is contraindicated in pregnancy and lactation (breastfeeding).

APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in chronic renal failure.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in liver failure.

APPLICATION FOR CHILDREN
Contraindicated in early childhood.

SPECIAL INSTRUCTIONS
With caution apply for congenital hyperbilirubinemia (syndromes Gilbert, Dubin-Johnson and Rotor).

Flurbiprofen may increase bleeding time, which increases the risk of bleeding from the gastrointestinal tract, especially with prolonged admission.

The greatest therapeutic effect is achieved with the use of flurbiprofen in the morning and evening hours.
During the administration of flurbiprofen, periodic monitoring of the pattern of peripheral blood and bleeding time is necessary.
If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the test.

When topical application in the form of eye drops to persons with herpetic keratitis in history, additional monitoring of patients is necessary.
When using the drug, there may be cases of delayed scarring of wounds, as well as cross-sensitivity to acetylsalicylic acid and other NSAIDs.
Impact on the ability to drive vehicles and manage mechanisms

During treatment, one should refrain from engaging in potentially dangerous activities that require increased attention and speed of mental and motor reactions.

DRUG INTERACTION
Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites.

With the simultaneous use of flurbiprofen reduces the effectiveness of uricosuric drugs, enhances the effect of anticoagulants (increases the risk of bleeding), antiplatelet agents, fibrinolytics, side effects of mineralocorticoids, GCS, estrogens;
reduces the effectiveness of antihypertensive and diuretics; enhances the hypoglycemic effect of sulfonylurea derivatives.
Acetylsalicylic acid increases the concentration of the drug in the plasma, ranitidine - reduces.

Antacids and colestyramine reduce the absorption of flurbiprofen.

With the simultaneous use of flurbiprofen increases the concentration in the blood of lithium preparations, methotrexate.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!